Forte Biosciences Inc (FBRX)

$0.56

-0.01

(-2.42%)▲

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $0.55
    $0.58
    $0.56
    downward going graph

    1.79%

    Downside

    Day's Volatility :4.86%

    Upside

    3.13%

    downward going graph
  • $0.38
    $1.03
    $0.56
    downward going graph

    32.14%

    Downside

    52 Weeks Volatility :63.11%

    Upside

    45.63%

    downward going graph

Returns

PeriodForte Biosciences IncSector (Health Care)Index (Russel 2000)
3 Months
-20.3%
6.5%
0.0%
6 Months
-23.6%
7.1%
0.0%
1 Year
-43.48%
9.8%
0.0%
3 Years
-98.16%
14.2%
-20.2%

Highlights

Market Capitalization
21.1M
Book Value
$0.79
Earnings Per Share (EPS)
-0.84
Wall Street Target Price
3.25
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-60.81%
Return On Equity TTM
-104.31%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-32.5M
Diluted Eps TTM
-0.84
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.59
EPS Estimate Next Year
-0.54
EPS Estimate Current Quarter
-0.16
EPS Estimate Next Quarter
-0.18

Analyst Recommendation

Buy
    87%Buy
    12%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for Forte Biosciences Inc(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 480.36%

Current $0.56
Target $3.25

Technicals Summary

Sell

Neutral

Buy

Forte Biosciences Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Forte Biosciences Inc
Forte Biosciences Inc
18.94%
-23.6%
-43.48%
-98.16%
-99.3%
Moderna, Inc.
Moderna, Inc.
-1.67%
18.26%
-0.21%
-64.15%
752.69%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.46%
13.21%
45.59%
84.19%
244.2%
Novo Nordisk A/s
Novo Nordisk A/s
-11.0%
18.31%
61.56%
186.46%
423.59%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.85%
14.43%
39.88%
147.45%
195.07%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Forte Biosciences Inc
Forte Biosciences Inc
NA
NA
NA
-0.59
-1.04
-0.61
NA
0.79
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.19
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.35
31.35
1.46
44.44
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
44.28
44.28
2.36
3.43
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.85
31.85
0.53
16.98
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Forte Biosciences Inc
Forte Biosciences Inc
Buy
$21.1M
-99.3%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$45.3B
752.69%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$116.9B
244.2%
31.35
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$572.0B
423.59%
44.28
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.7B
195.07%
31.85
39.46%

Insights on Forte Biosciences Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 105.1%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 284.7%

Institutional Holdings

  • Tybourne Capital Management (HK) Ltd

    9.95%

  • Perceptive Advisors LLC

    8.96%

  • Bvf Inc

    8.18%

  • Cable Car Capital LLC

    5.58%

  • Fred Alger Management, LLC

    5.05%

  • Farallon Capital Management, L.L.C.

    4.97%

Company Information

we are driven by a vision to end cancer mortality. our company was founded on this vision in 2007. tocagen’s mission is to become a leading biopharmaceutical company for the treatment of cancer using cancer-selective gene therapy products based on our retroviral gene therapy platforms to increase lifespan, initially for patients with advanced local and metastatic cancer. our broadly applicable product candidates are designed to activate a patient’s immune system against their cancer from within. at the core of our approach is a novel gene therapy platform that utilizes retroviral replicating vectors (rrvs), which are designed to selectively deliver therapeutic genes into the dna of cancer cells. our proprietary platform is designed to fight cancer through a combination of mechanisms of action without the autoimmune toxicities that patients commonly experience with other treatments. in other words, our technology is designed to combat cancer with fewer side effects, keeping patients’ he

Organization
Forte Biosciences Inc
Employees
11
CEO
Dr. Paul A. Wagner Ph.D.
Industry
Health Technology

Discover More

FAQs